Patients need not be concerned
SASKATOON, March 19, 2014 /CNW/ - Amid the speculation and concern
surrounding the supply of medical marijuana available to Canadians on
April 1st when the new Marihuana for Medical Purposes Regulations (MMPR) comes into full effect, today CanniMed Ltd. announced that their
supply of pharmaceutical-grade cannabis will be sufficient to fulfil an
additional 10,000 new patient orders immediately upon patient
registration. Additionally, CanniMed's facility expansion scheduled to
be complete by the end of June 2014 will increase the total patient
capacity to 25,000.
"As soon as we received our license in the Fall of 2013, we
strategically planned to increase our production output to ensure that
Canadians who rely on medical marijuana for their chronic or terminal
illnesses wouldn't be left without a supply of medication," said Brent
Zettl, CEO, CanniMed Ltd. "Right now, we have produced enough of our
four varieties of pharmaceutical-grade cannabis for those who will be
transitioning their license under the new system, and our production
facility expansion is almost complete to ensure our production output
expands exponentially by the summer."
CanniMed Ltd. currently produces four varieties of medical marijuana
containing a range of the two main active ingredients:
delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD):
CanniMed 22•1 - containing 22.0% THC and 0.7% CBD
CanniMed 17•1 - containing 17.0% THC and 0.7% CBD
CanniMed 12•0 - containing 12.5% THC and less than 0.5% CBD
CanniMed 9•9 - containing 9.0% THC and 9.5% CBD
THC is thought to be responsible for the psychoactive effects and has
also been shown to be responsible for medical marijuana's
immunosuppressive, anti-inflammatory and analgesic properties. CBD,
which lacks nearly any psychoactive effect, is responsible for giving
medical marijuana its anti-inflammatory, analgesic, anti-nausea,
anti-emetic, anti-psychotic, anti-ischemic, anxiolytic and
For those patients who previously received their medical marijuana
supply from Health Canada, the CanniMed 12•0 product is the same
variety as they have relied on in the past. As of April 30, 2014,
CanniMed will also be making available CanniMed 1•13 (0.7% THC; 13.0%
CBD) and patients are welcome to put in their order now for shipment in
To date, CanniMed Ltd. has seamlessly transitioned a handful of patients
through to the new MMPR program.
"We are actively encouraging patients to connect with us regarding our
products and what varieties of pharmaceutical-grade cannabis we should
consider producing in the future," added Mr. Zettl. "It continues to be
our goal to provide our patients with a wide range of varieties
consistent with the needs expressed for managing the effects of
different ailments and diseases."
CanniMed Ltd. was the first producer to be licensed under the new Marihuana for Medical Purposes Regulations (MMPR). Our pharmaceutical-grade marijuana is produced under Good
Manufacturing Practices (GMP) regulations, the criteria used to
manufacture all pharmaceuticals in Canada.
We are committed to standardizing care by taking a leadership role in
closing the gap between the anecdotal benefit of medical marijuana and
evidenced-based scientific research. Our goal is to provide improved
access for Canadians who rely on medical marijuana through scientific
collaborations with external partners including academic institutions
and healthcare professionals.
Our primary focus is patient safety by strictly following a 281 point
quality control process.
Image with caption: "CanniMed Ltd. logo (CNW Group/CanniMed Ltd.)". Image available at: http://photos.newswire.ca/images/download/20140319_C6122_PHOTO_EN_38153.jpg
SOURCE: CanniMed Ltd.
For further information:
Dara Willis Communications